Drug Profile
DX 0314
Alternative Names: DX-0314Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator DermaXon
- Class
- Mechanism of Action Retinoic acid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 19 Jul 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route)